Promoter holding
64.27%
OP
Orchid Pharma Limited - Due diligence report
A 360° intelligence report on Orchid Pharma: trust score, financial health, credit view, compliance, directors, growth and distress signals …
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹449
Save ₹251
excl. GST
Or from ₹279/report with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Orchid Pharma — 360° Intelligence Report
Generated from MCA filings & public records75/100
Trust Score
Low Risk
Orchid Pharma is assessed as Low Risk with a Trust Score of 75/100. Orchid Pharma is an active public limited indian non-government company incorporated in 1992, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a high compliance risk and low financial risk profile.
Report generated on 27 Jul 2026 from the latest processed filings. Orchid Pharma Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreLow Risk
75/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreCaution Indicated
32/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
95/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreLow Risk
95/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
90/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
85/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
90/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Standalone · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 95/100 Low Risk
- Liabilities ≈ 38% EBITDA - serviceable.
- Moderate gearing (D/E 1.42).
- Working-capital cover adequate.
- Profitable - internal accruals available.
- Externally credit-rated (BBB-).
Charges position: 3 open (366.50 cr) · 176 satisfied (15,353.51 cr).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| Sbicap Trustee Company Limited | 2 | 48.0 cr |
| Bank Of India | 11 | 48.0 cr |
| State Bank Of India | 13 | 48.0 cr |
| Allahabad Bank | 10 | 48.0 cr |
| Axis Trustee Services Limited | 1 | 48.0 cr |
| Punjab National Bank | 12 | 48.0 cr |
Compliance Score: 32/100 Caution Indicated
- Company status is Active as per MCA.
- Annual filings current (balance sheet Mar 2025).
- Flagged by authority: SEBI, BANKS, NSE.
- Litigation present in 5 court forum(s).
- 1 auditor resignation(s) filed - latest: SNB ASSOCIATES on 2017-09-11.
- Delayed payments to MSME suppliers disclosed (126 disclosure(s)).
- 4 active GST registration(s).
Legal cases on record (5)
05
Director Intelligence
Stability score: 90/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| MRIDUL DHANUKA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| ARJUN DHANUKA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| TANU SINGLA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| DHARAM VIR | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| MANISH DHANUKA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SUNIL KUMAR GUPTA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| SHUBHA SINGH | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| RAM GOPAL AGARWAL | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| KAPIL DAYYA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| MANOJ KUMAR GOYAL | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 10 directors on the board.
- No disqualified or deactivated DINs.
- 2 director exit(s) in the last 3 years.
- Average tenure above 5 years.
Director & KMP remuneration (FY 2024)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2025 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
Dhanuka Laboratories Limited
Subsidiaries
1
Group entities
3
Capital events
3 allotment(s) · 1 transfer(s)
Promoters hold a minority stake - exact percentages are part of the full report.
| Group entity | Relationship | % held |
|---|---|---|
| Orchid Bio-pharma Limited | Subsidiary Company | 74.00% |
| Dhanuka Laboratories Limited | Holding Company | 74.00% |
| Orbion Pharmaceuticals Private Limited | Associate Company | 74.00% |
Key managerial personnel: MRIDUL DHANUKA (Whole-time director) · MANISH DHANUKA (Managing Director) · SUNIL KUMAR GUPTA (CFO)
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 85 · Distress 90
Growth signals & trust indicators
Revenue acceleration: +2.1x over 4 year(s).
Profit expanded 24% year-on-year.
EPFO headcount growing - hiring signal.
Operating for 34+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Compliance score is weak (32/100).
3 open charge(s) registered - assets are encumbered.
1 auditor resignation(s) on record - review the stated reasons.
MSME payment delays disclosed - latest outstanding 3.57 cr.
5 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence62/100
Review suggested
Suitability as a supplier / customer counterparty.
- Check the compliance flags before onboarding.
- No distress signals on file.
- Financial filings available for verification.
Banker assessment79/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- 3 open charge(s) of 366.50 cr already registered.
- Compliance gaps should be priced into terms.
Investor view86/100
Positive growth indicators
Growth quality and scalability through an investor lens.
- 3 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management team looks stable.
09
MCA Filings & Events Timeline
Latest 15 events20 Sep 2025
Last AGM held
Annual general meeting
17 Jul 2025
Charge created
Hdfc Bank Limited - 142.50 cr
31 Mar 2025
Latest balance sheet
Filed with ROC
20 Aug 2024
Director ceased
SHUBHA SINGH
23 May 2024
Director appointed
SHUBHA SINGH (Director)
26 Dec 2023
Director appointed
KAPIL DAYYA (Company Secretary)
29 Nov 2023
Charge satisfied
Hdfc Bank Limited
26 Nov 2023
Director ceased
ARJUN DHANUKA
20 Oct 2023
Director appointed
ARJUN DHANUKA (Director)
02 Aug 2023
Charge created
Hdfc Bank Limited - 50.00 cr
20 Jul 2023
Charge satisfied
Others
27 Aug 2022
Charge created
Yes Bank Limited - 75.00 cr
04 Mar 2022
Charge satisfied
Punjab National Bank
15 Nov 2021
Charge created
Hdfc Bank Limited - 149.00 cr
08 Jun 2021
Charge satisfied
Punjab National Bank
10
Key Observations
Auto-generated from the data aboveRevenue grew 0.86 over the last 4 financial year(s).
Net profit margin moved from 61% to 38%.
Debt-to-equity stands at 1.42 - manageable leverage.
Net worth is positive.
10 active director(s) / partner(s); board looks stable and experienced.
4 active GST registration(s) indicate ongoing business operations.
Operates a group structure with 1 subsidiary(ies) - assess on a consolidated basis.
Carries an external credit rating of BBB- from Care.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a minority stake as per the FY 2025 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 3 security allotment(s) - amounts available in the full report.
7 overseas direct investment(s) (ODI) on record - international footprint.
| Company | CIN | Location |
|---|---|---|
| Archroma | U20297MH2013FTC242571 | Mumbai, Maharashtra, India |
| Manas Agro Industries & Infrastructure Limited | U10721MH2012PLC235369 | Mumbai, Maharashtra, India |
| Procter & Gamble Health | L99999MH1967PLC013726 | Mumbai, Maharashtra, India |
| Dharmaj Crop Guard | L24100GJ2015PLC081941 | Ahmedabad, Gujarat, India |
| Cleanscience | L24114PN2003PLC018532 | Pune City, Maharashtra, India |
| Chemspec | U24114MH1975PTC018665 | Navi Mumbai, Maharashtra, India |
| Innova Captab | L24246MH2005PLC150371 | Thane, Maharashtra, India |
| Bajaj | L01110RJ2006PLC047173 | Udaipur, Rajasthan, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Orchid Pharma before audits and certifications: compliance score 32/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Orchid Pharma: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Favourable lending indicators. Credit risk score 95/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Positive growth indicators. Growth score 85/100, margin trends, ownership structure and peer set for Orchid Pharma - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Review suggested. Trust score 75/100, distress signals and MSME payment-delay disclosures - know whether Orchid Pharma pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (5 case(s) on record), regulatory flags, charge documents trail and director networks for Orchid Pharma - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Orchid Pharma an active company?
Orchid Pharma has MCA status “Active” with a compliance score of 32/100 (Caution Indicated).
Is Orchid Pharma financially healthy?
Orchid Pharma has a Financial Health Score of 95/100 (Low Risk) based on its filed financial statements.
Should I do business with Orchid Pharma?
Its overall Trust Score is 75/100 (Low Risk). Vendor verdict: Review suggested. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Orchid Pharma?
The ultimate holding entity is Dhanuka Laboratories Limited. 10 active director(s) are on record.
Does Orchid Pharma have loans or charges against its assets?
3 open charge(s) are registered against its assets, and 176 earlier charge(s) stand satisfied.
Is Orchid Pharma up to date with its ROC filings?
Annual filings current (balance sheet Mar 2025). Overall compliance score: 32/100 (Caution Indicated).
Is it risky to lend to Orchid Pharma?
Its Credit Risk Score is 95/100 (Low Risk). Banker verdict: Favourable lending indicators.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
